GRANULES Q2 : CONS NET PROFIT UP 39.2% AT ₹182 CR (YOY), UP 1.0% (QOQ)

• Revenue up 20.3% at ₹1,560 Cr (YOY), up 5.6% (QOQ). • EBITDA up 25.7% at ₹348 Cr (YOY); margins 22.3% v 21.4% (YOY), 23.1% (QOQ). • USFDA inspected Gagillapur facility in October 2026 and issued Form FDA 483; no observations on data integrity or cross-contamination. • 24,982,906 warrants converted during the quarter; balance subscription of ₹1,096 Cr received, equity shares allotted at ₹585 each.

Granules India Limited

Open attachment

← Back to feed